Search

Your search keyword '"Ghia, Paolo"' showing total 212 results

Search Constraints

Start Over You searched for: Author "Ghia, Paolo" Remove constraint Author: "Ghia, Paolo" Publisher elsevier inc. Remove constraint Publisher: elsevier inc.
212 results on '"Ghia, Paolo"'

Search Results

4. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

5. Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL

6. High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL

7. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

9. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

10. Genetic and phenotypic attributes of splenic marginal zone lymphoma

12. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

13. IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

14. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

15. MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study

18. CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/ SLL)

19. CLL-120 Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study

20. CLL-114 BRUIN CLL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

23. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation

24. HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment

25. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations

26. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

28. Molecular Evidence for Antigen Drive in the Natural History of Mantle Cell Lymphoma

29. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study

31. Final Analysis of the RESONATE-2 Study: Up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

32. CLL-057 Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study

33. CLL-076 Final Analysis of the RESONATE-2 Study: up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

36. Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study

37. Genomic profiling for clinical decision making in lymphoid neoplasms

38. Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

39. Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

41. Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study

42. Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up

43. Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL

44. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

45. Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

46. A Comprehensive DNA Methylome Analysis of Stereotyped and Non-Stereotyped CLL Reveals an Epigenetic Signature with Strong Clinical Impact Encompassing IGHV Status, Stereotypes and IGLV3-21R110

47. Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

Catalog

Books, media, physical & digital resources